Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000815235 | SCV000955684 | likely benign | Osteogenesis imperfecta type I | 2023-08-28 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV004028845 | SCV005032112 | uncertain significance | Cardiovascular phenotype | 2023-10-17 | criteria provided, single submitter | clinical testing | The p.Q42R variant (also known as c.125A>G), located in coding exon 2 of the COL1A1 gene, results from an A to G substitution at nucleotide position 125. The glutamine at codon 42 is replaced by arginine, an amino acid with highly similar properties. This amino acid position is not well conserved in available vertebrate species. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |
Breakthrough Genomics, |
RCV004693361 | SCV005192962 | uncertain significance | not provided | criteria provided, single submitter | not provided | ||
Gene |
RCV004693361 | SCV005327284 | likely benign | not provided | 2019-03-20 | criteria provided, single submitter | clinical testing | See Variant Classification Assertion Criteria. |
Fulgent Genetics, |
RCV005021240 | SCV005649561 | uncertain significance | Osteogenesis imperfecta with normal sclerae, dominant form; Osteogenesis imperfecta, perinatal lethal; Osteogenesis imperfecta type III; Infantile cortical hyperostosis; Ehlers-Danlos syndrome, arthrochalasia type; Osteogenesis imperfecta type I; Osteoporosis; Combined osteogenesis imperfecta and Ehlers-Danlos syndrome 1 | 2024-01-02 | criteria provided, single submitter | clinical testing |